{"dataset":{"id":"45727","dataset_id":"on007864","name":"Neuroepo multisession Phase II and III","description":"A randomized, placebo-controlled clinical trial investigating the neuroprotective and neuromodulatory effects of intranasal NeuroEPO (erythropoietin) in Parkinson's disease patients. The dataset comprises multisession EEG recordings and clinical assessments collected at two timepoints: baseline (pre-intervention) and 9-month post-intervention, with the goal of examining whether NeuroEPO-related cognitive and motor effects are mediated by changes in EEG source activity and brain function.","owner_user_id":15,"status":"active","github_repo":"nemarDatasets/on007864","concept_doi":"10.82901/nemar.on007864","latest_version_doi":"10.82901/nemar.on007864.v1.0.0","created_at":"2026-06-19 06:01:40","updated_at":"2026-07-22 02:37:59","zenodo_concept_id":null,"is_sandbox":0,"visibility":"public","ezid_status":"public","enrichment_json":"{\n  \"version\": \"2.0\",\n  \"pipeline_stage\": \"enriched\",\n  \"title\": \"Neuroepo multisession Phase II and III\",\n  \"description\": \"A randomized, placebo-controlled clinical trial investigating the neuroprotective and neuromodulatory effects of intranasal NeuroEPO (erythropoietin) in Parkinson's disease patients. The dataset comprises multisession EEG recordings and clinical assessments collected at two timepoints: baseline (pre-intervention) and 9-month post-intervention, with the goal of examining whether NeuroEPO-related cognitive and motor effects are mediated by changes in EEG source activity and brain function.\",\n  \"methods_description\": \"Participants were enrolled in a randomized, placebo-controlled study with NeuroEPO administered intranasally according to protocol (Cuban Public Registry RPCEC00000233-En) or placebo. Clinical and EEG assessments were conducted at baseline (pre-intervention) and after 9 months of intervention completion. Motor performance was assessed using the Unified Parkinson Disease Rating Scale MDS UPDRS III by certified neurologists. Cumulative treatment exposure was quantified as total NeuroEPO dose. EEG source localization analysis was performed to examine changes in brain activity as potential mediators of clinical outcomes.\",\n  \"license\": \"CC0\",\n  \"dataset_type\": \"raw\",\n  \"authors\": {\n    \"Maria Luisa Bringas Vega\": {},\n    \"Lilia Morales Chacon\": {},\n    \"Ivonne Pedroso Ibanez\": {}\n  },\n  \"keywords\": [\n    {\n      \"term\": \"EEG\"\n    },\n    {\n      \"term\": \"Parkinson's disease\"\n    },\n    {\n      \"term\": \"erythropoietin\"\n    },\n    {\n      \"term\": \"NeuroEPO\"\n    },\n    {\n      \"term\": \"neuroprotection\"\n    },\n    {\n      \"term\": \"randomized controlled trial\"\n    },\n    {\n      \"term\": \"placebo-controlled\"\n    },\n    {\n      \"term\": \"source localization\"\n    },\n    {\n      \"term\": \"motor assessment\"\n    },\n    {\n      \"term\": \"clinical trial\"\n    },\n    {\n      \"term\": \"Phase II\"\n    },\n    {\n      \"term\": \"Phase III\"\n    },\n    {\n      \"term\": \"UPDRS\"\n    },\n    {\n      \"term\": \"source reconstruction\"\n    }\n  ],\n  \"related_identifiers\": [\n    {\n      \"identifier\": \"https://github.com/nemarDatasets/on007864\",\n      \"identifier_type\": \"URL\",\n      \"relation_type\": \"IsDescribedBy\"\n    },\n    {\n      \"identifier\": \"10.18112/openneuro.ds007864\",\n      \"identifier_type\": \"DOI\",\n      \"relation_type\": \"IsVersionOf\"\n    },\n    {\n      \"identifier\": \"10.18112/openneuro.ds007864.v1.0.0\",\n      \"identifier_type\": \"DOI\",\n      \"relation_type\": \"IsDerivedFrom\"\n    },\n    {\n      \"identifier\": \"https://nemar.org/dataset/on007864\",\n      \"identifier_type\": \"URL\",\n      \"relation_type\": \"IsDescribedBy\"\n    }\n  ],\n  \"funding_references\": [\n    {\n      \"funder_name\": \"National Key R&D Program of China\",\n      \"award_number\": \"2024YFE0215100\"\n    }\n  ],\n  \"resource_type_specific\": \"EEG Dataset\",\n  \"modalities\": [\n    \"eeg\"\n  ],\n  \"sizes\": [\n    \"498.4 MB (91 files)\"\n  ],\n  \"formats\": [\n    \".edf\",\n    \".json\",\n    \".md\",\n    \".tsv\",\n    \".yml\"\n  ],\n  \"source_hash\": \"357d12421c971db81e28501ebc63324c3820c2cb464b9769b192f1980ebcae7f\"\n}","last_activity_at":"2026-06-19 06:01:40","source":"openneuro","source_id":"ds007864","subject_count":45,"modalities":"eeg","age_min":null,"age_max":null,"file_size":499630485,"total_files":609,"tasks":"resteyesclosed","metadata_columns_error":null,"staleness_warn_stage":null,"staleness_admin_notified_at":null,"authors":"Maria Luisa Bringas Vega, Lilia Morales Chacon, Ivonne Pedroso Ibanez","license":"CC0","readme":"[![DOI](https://img.shields.io/badge/DOI-10.82901%2Fnemar.on007864-blue)](https://doi.org/10.82901/nemar.on007864)\n\nErythropoietin (EPO) and EPO-derived formulations have been proposed as neuroprotective and neuromodulatory agents with \npleiotropic actions that extend beyond erythropoiesis, including anti-inflammatory and anti-oxidative effects, modulation of apoptosis-\nrelated signaling, and support of cellular resilience under stress (Maiese et al., 2005; Rey et al., 2019). In Parkinson's disease-relevant \ncontexts, EPO has been linked to mechanisms involving mitochondrial metabolism and pathways relevant to dopaminergic \nvulnerability, suggesting a plausible route by which exposure could influence systems-level brain function (Rey et al., 2021). At the \nmolecular level, EPO-related transcriptional responses in the brain have been shown to engage synaptic plasticity-associated gene \nprograms, supporting the interpretation that treatment exposure could be accompanied by functional reorganization rather than solely \nsymptomatic modulation (Mengozzi et al., 2012). Clinically and translationally, intranasal NeuroEPO has been evaluated for short-term \ntolerance in Parkinson's disease, providing practical context for the formulation and administration route used in patient studies \n(Garcia-Llano et al., 2021). Moreover, prior work has reported that NeuroEPO-related cognitive effects in Parkinson's disease patients \ncan be statistically mediated by EEG source activity, providing precedent for an exposure ? EEG mediator ? outcome framework in \nthis setting (Bringas Vega et al., 2022).\nParticipants were enrolled in a randomized, placebo-controlled study. NeuroEPO exposure was administered according to the \nintervention protocol (Cuban Public Registry of Clinical Trials: RPCEC00000233-En; https://rpcec.sld.cu/en/trials/RPCEC00000233\n-En ), while placebo participants received identical procedures without active compound. Cumulative treatment exposure was \nquantified as total NeuroEPO dose; placebo participants were coded as dose = 0. Clinical and EEG assessments were conducted at \nbaseline (pre-intervention) and after 9 months of completion of the intervention period (post-intervention).\nBaseline demographic and clinical characteristics were summarized for the NeuroEPO and placebo groups. Baseline variables \nincluded age (years), education (years), and study-coded measures of disease duration/progression and motor severity available in \nthe source dataset. The motor performance was assessed by two certified neurologists using the Unified Parkinson Disease Rating \nScale MDS UPDRS III item scores collected at pre  and post-intervention visits (Goetz et al., 2008), where the severity variable was \nrecorded as an ordinal 0-4 grade, with lower values indicating better motor status, and was used for baseline description only.\n","bids_version":"1.2.0","sessions_count":2,"publish_date":null,"embedding_dirty":0,"license_tier":"public","zarr_status":"failed","zarr_converted_at":null,"zarr_store_count":null,"zarr_index_etag":null,"zarr_source_commit":null,"archive_status":"ready","archive_size":421778,"archive_retry_count":0,"records_status":"ready","archive_skip_reason":null,"zarr_errors":84,"zarr_failure_count":84,"zarr_deterministic":1,"zarr_failed_at":"2026-09-06 02:39:27","num_dataset_citations":0,"num_datapaper_citations":0,"n_channels":21,"electrode_system":"10-20","has_hed":0,"hed_version":null,"is_exemplar":0,"bytes_present":498422969,"data_complete":1,"withdrawn_at":null,"withdrawn_reason":null,"archive_complete":null,"archive_absent_files":null,"archive_declared_files":null,"zarr_pool_breaks":0,"total_recording_duration":null,"recording_duration_min":null,"recording_duration_max":null,"recording_count":null,"recordings_unavailable":null,"recordings_measured":null,"channel_count_min":null,"channel_count_max":null,"sampling_frequency":200,"power_line_frequency":60,"eeg_reference":"linked earlobes (A1 and A2)","placement_scheme":"10-20","sweep_stamps":"{\"enrichment_updated_at\":\"2026-07-22 02:37:48\",\"metadata_updated_at\":\"2026-07-22 02:37:57\",\"archive_checked_at\":\"2026-06-19 06:10:54\",\"zarr_checked_at\":null,\"records_checked_at\":\"2026-06-19 06:11:10\",\"citations_updated_at\":null,\"channel_montage_checked_at\":\"2026-06-28 23:59:23\",\"hed_checked_at\":\"2026-06-30 05:46:16\",\"data_checked_at\":null,\"availability_report_at\":\"2026-07-23 01:34:05\",\"recording_stats_at\":null,\"signal_defaults_at\":\"2026-09-02 12:59:06\"}","participants":45,"num_citations":0,"latest_version":"v1.0.0","zarr_verify_status":null,"zarr_verified_at":null,"owner_username":"nemarAdmin","owner_github":"nemarAdmin","file_size_formatted":"476 MB","zarr_data_failures":{"count":84,"detail_ref":"zarr/index.json","pending":0,"discovered":84},"zarr_index_url":null,"attestation_deposit_type":null,"attestation_key_status":null,"attestation_deidentified":null,"attestation_no_duplicate":null,"attestation_upstream_source":null,"attestation_accepted_at":null}}